HRAS Antikörper (C-Term)

Produktnummer ABIN2857002

Zitiert in 4+ Publikationen. Der Kaninchen Polyklonal anti-HRAS Antikörper (ABIN2857002) detektiert spezifisch HRAS in WB, IF, IHC (p) und ICC. Dieser Antikörper reagiert spezifisch mit Proben aus Human, Maus und Ratte.

Kurzübersicht für HRAS Antikörper (C-Term) (ABIN2857002)

Target: HRAS (HRas proto-oncogene, GTPase (HRAS))

Reaktivität: Human, Maus, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser HRAS Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunocytochemistry (ICC)

Produktdetails anti-HRAS Antikörper

Bindungsspezifität: C-Term

Produktmerkmale: Rabbit Polyclonal antibody to H-Ras (v-Ha-ras Harvey rat sarcoma viral oncogene homolog)
H-Ras antibody

Aufreinigung: Purified by antigen-affinity chromatography.

Immunogen: Carrier-protein conjugated synthetic peptide encompassing a sequence within the C-terminus region of human H-Ras.

Anwendungsinformationen

Applikationshinweise: WB: 1:500-1:3000, IHC-P: 1:100-1:1000, ICC/IF: 1:100-1:1000.
Not yet tested in other applications.
Optimal working dilutions should be determined experimentally by the end user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: 0.1M Tris, 0.1M Glycine, 20 % Glycerol ( pH 7).
0.01 % Thimerosal was added as a preservative.

Konservierungsmittel: Thimerosal (Merthiolate)

Vorsichtsmaßnahmen: This product contains Thimerosal (Merthiolate): a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Keep as concentrated solution. Aliquot and store at -20°C or below.
Avoid multiple freeze-thaw cycles.

Referenzen für anti-HRAS Antikörper (ABIN2857002)

Basu, Lee, Salotti, Basu, Sakchaisri, Xiao, Walia, Westlake, Morrison, Johnson: "Oncogenic RAS-Induced Perinuclear Signaling Complexes Requiring KSR1 Regulate Signal Transmission to Downstream Targets." in: Cancer research, Vol. 78, Issue 4, pp. 891-908, (2019) (PubMed).

Brandt, Albers, Hejhal, Pfundstein, Gonçalves, Catalano, Wild, Frew: "Mouse genetic background influences whether HrasG12V expression plus Cdkn2a knockdown causes angiosarcoma or undifferentiated pleomorphic sarcoma." in: Oncotarget, Vol. 9, Issue 28, pp. 19753-19766, (2018) (PubMed).

Gao, Wang, Jin, Hu, Duan, Shi, Du, Song, Yang, Li, Han, Zhao, Zhang, Fan, Miao: "Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells." in: Breast cancer research : BCR, Vol. 20, Issue 1, pp. 112, (2018) (PubMed).

Brandt, Albers, Hejhal, Catalano, Wild, Frew: "Oncogenic HrasG12V expression plus knockdown of Cdkn2a using ecotropic lentiviral vectors induces high-grade endometrial stromal sarcoma." in: PLoS ONE, Vol. 12, Issue 10, pp. e0186102, (2017) (PubMed).

Details zu HRAS

Target: HRAS (HRas proto-oncogene, GTPase (HRAS))

Andere Bezeichnung: H-Ras

Gen-ID: 3265

Pathways: p53 Signalweg, MAPK Signalweg, RTK Signalweg, Fc-epsilon Rezeptor Signalübertragung, EGFR Signaling Pathway, Neurotrophin Signalübertragung, Hepatitis C, Autophagie, Signaling Events mediated by VEGFR1 and VEGFR2, Signaling of Hepatocyte Growth Factor Receptor, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling, BCR Signaling